GlassScriptPhysician profile
Douglas C Wallace
NPI 1063451144
$1,210.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $136.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $222.42 | 2019-2020 | |
| Novo Nordisk INC | $188.34 | 2019-2020 | |
| Lilly USA, LLC | $169.34 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.33 | 2019 | |
| Amgen INC. | $56.18 | 2019-2020 | |
| Astellas Pharma US INC | $55.09 | 2019-2020 | |
| Amarin Pharma, INC. | $45.77 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $37.38 | 2019 | |
| Shire North American Group INC | $35.37 | 2019 | |
| Pfizer INC. | $28.16 | 2019-2020 | |
| Abbvie INC. | $27.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.